Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment

In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component o...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & developmental immunology 2010-01, Vol.2010 (2010), p.1-17
Main Authors: Hamšíková, Eva, Vonka, Vladimír, Humlová, Zuzana, Roth, Zdeněk, Šterzl, Ivan, Králíková, Petra, Klamová, Hana, Janatková, Ivana, Malíčková, Karin
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - therapeutic use
Benzamides
C-Reactive Protein - analysis
Complement System Proteins - analysis
Dasatinib
E coli
Female
Humans
Hydroxyurea - therapeutic use
Imatinib Mesylate
Immune system
Immunity, Innate
Immunoglobulins - blood
Immunologic Factors - therapeutic use
Immunology
Interferon-alpha - therapeutic use
Interleukin-6 - blood
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy
Longitudinal Studies
Lupus
Male
Mathematical models
Middle Aged
Piperazines - therapeutic use
Protein Kinase Inhibitors - therapeutic use
Pyrimidines - therapeutic use
T-Lymphocytes - metabolism
Teaching hospitals
Thiazoles - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c530t-956eb0d75020104dd71ab110359b7abdc8889ea79ca106c9aa53549037f4047a3
cites cdi_FETCH-LOGICAL-c530t-956eb0d75020104dd71ab110359b7abdc8889ea79ca106c9aa53549037f4047a3
container_end_page 17
container_issue 2010
container_start_page 1
container_title Clinical & developmental immunology
container_volume 2010
creator Hamšíková, Eva
Vonka, Vladimír
Humlová, Zuzana
Roth, Zdeněk
Šterzl, Ivan
Králíková, Petra
Klamová, Hana
Janatková, Ivana
Malíčková, Karin
description In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component of complement, the C-reactive protein, interleukin 6, the composition of lymphocyte population and the production of some cytokines by stimulated CD3+ cells. Eleven of these patients were followed longitudinally. After treatment with hydroxyurea, interferon alpha, imatinib mesylate and dasatinib, or various combinations thereof, hematological remission was achieved in all patients and complete cytogenetic remission in nine of them. There was a nearly general tendency towards normalization of the abnormalities observed in the patients at their enrollment.
doi_str_mv 10.1155/2010/137320
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c618fc624da74bea9a63dc767bf29762</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c618fc624da74bea9a63dc767bf29762</doaj_id><sourcerecordid>2292562701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c530t-956eb0d75020104dd71ab110359b7abdc8889ea79ca106c9aa53549037f4047a3</originalsourceid><addsrcrecordid>eNqFkktv1DAQgC0Eou3CiTMo4lIJtNSv2PEFCUU8VlpED-VsTWxn4yWJWzuh6r_HS8qKcuFky_P583hmEHpB8DtCyvKCYoIvCJOM4kfolEiO17Rk-PFxT-kJOktpj3Heq-opOqGEKIklO0Vt3cG4c6kIbbEZhnkMfdh5A31xGUPr-xzxY3EJk3fjlIpbP3VF3cUwelN8vXN98LbYuvmHGzwcyKlzRR3mmNzBeBUdTEO--Qw9aaFP7vn9ukLfP328qr-st98-b-oP27XJGU9rVQrXYCtLfPgUt1YSaAjBrFSNhMaaqqqUA6kMECyMAihZyRVmsuWYS2ArtFm8NsBeX0c_QLzTAbz-fRDiTkOcvOmdNoJUrRGUW5C8caBAMGukkE1LlRQ0u94vruu5GZw1-RsR-gfSh5HRd3oXfmqGMWcVyYLze0EMN7NLkx58Mq7vYXRhTrqilOX3cx9W6PU_5D7XcMyV0lUplFSS8gy9XSATQ0rRtcdUCNaHSdCHoullEjL96u_sj-yf1mfgzQJ0frRw6_9je7nALiOuhSPMeSW4YL8AvonEFw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>856979724</pqid></control><display><type>article</type><title>Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Hamšíková, Eva ; Vonka, Vladimír ; Humlová, Zuzana ; Roth, Zdeněk ; Šterzl, Ivan ; Králíková, Petra ; Klamová, Hana ; Janatková, Ivana ; Malíčková, Karin</creator><contributor>Berzins, Stuart</contributor><creatorcontrib>Hamšíková, Eva ; Vonka, Vladimír ; Humlová, Zuzana ; Roth, Zdeněk ; Šterzl, Ivan ; Králíková, Petra ; Klamová, Hana ; Janatková, Ivana ; Malíčková, Karin ; Berzins, Stuart</creatorcontrib><description>In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component of complement, the C-reactive protein, interleukin 6, the composition of lymphocyte population and the production of some cytokines by stimulated CD3+ cells. Eleven of these patients were followed longitudinally. After treatment with hydroxyurea, interferon alpha, imatinib mesylate and dasatinib, or various combinations thereof, hematological remission was achieved in all patients and complete cytogenetic remission in nine of them. There was a nearly general tendency towards normalization of the abnormalities observed in the patients at their enrollment.</description><identifier>ISSN: 1740-2522</identifier><identifier>ISSN: 2314-8861</identifier><identifier>EISSN: 1740-2530</identifier><identifier>EISSN: 2314-7156</identifier><identifier>DOI: 10.1155/2010/137320</identifier><identifier>PMID: 21197073</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Puplishing Corporation</publisher><subject>Adult ; Antineoplastic Agents - therapeutic use ; Benzamides ; C-Reactive Protein - analysis ; Complement System Proteins - analysis ; Dasatinib ; E coli ; Female ; Humans ; Hydroxyurea - therapeutic use ; Imatinib Mesylate ; Immune system ; Immunity, Innate ; Immunoglobulins - blood ; Immunologic Factors - therapeutic use ; Immunology ; Interferon-alpha - therapeutic use ; Interleukin-6 - blood ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy ; Longitudinal Studies ; Lupus ; Male ; Mathematical models ; Middle Aged ; Piperazines - therapeutic use ; Protein Kinase Inhibitors - therapeutic use ; Pyrimidines - therapeutic use ; T-Lymphocytes - metabolism ; Teaching hospitals ; Thiazoles - therapeutic use ; Treatment Outcome</subject><ispartof>Clinical &amp; developmental immunology, 2010-01, Vol.2010 (2010), p.1-17</ispartof><rights>Copyright © 2010 Zuzana Humlová et al.</rights><rights>Copyright © 2010 Zuzana Humlová et al. Zuzana Humlová et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2010 Zuzana Humlová et al. 2010 Copyright © 2010 Zuzana Humlová et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c530t-956eb0d75020104dd71ab110359b7abdc8889ea79ca106c9aa53549037f4047a3</citedby><cites>FETCH-LOGICAL-c530t-956eb0d75020104dd71ab110359b7abdc8889ea79ca106c9aa53549037f4047a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/856979724/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/856979724?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21197073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Berzins, Stuart</contributor><creatorcontrib>Hamšíková, Eva</creatorcontrib><creatorcontrib>Vonka, Vladimír</creatorcontrib><creatorcontrib>Humlová, Zuzana</creatorcontrib><creatorcontrib>Roth, Zdeněk</creatorcontrib><creatorcontrib>Šterzl, Ivan</creatorcontrib><creatorcontrib>Králíková, Petra</creatorcontrib><creatorcontrib>Klamová, Hana</creatorcontrib><creatorcontrib>Janatková, Ivana</creatorcontrib><creatorcontrib>Malíčková, Karin</creatorcontrib><title>Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment</title><title>Clinical &amp; developmental immunology</title><addtitle>Clin Dev Immunol</addtitle><description>In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component of complement, the C-reactive protein, interleukin 6, the composition of lymphocyte population and the production of some cytokines by stimulated CD3+ cells. Eleven of these patients were followed longitudinally. After treatment with hydroxyurea, interferon alpha, imatinib mesylate and dasatinib, or various combinations thereof, hematological remission was achieved in all patients and complete cytogenetic remission in nine of them. There was a nearly general tendency towards normalization of the abnormalities observed in the patients at their enrollment.</description><subject>Adult</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>C-Reactive Protein - analysis</subject><subject>Complement System Proteins - analysis</subject><subject>Dasatinib</subject><subject>E coli</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxyurea - therapeutic use</subject><subject>Imatinib Mesylate</subject><subject>Immune system</subject><subject>Immunity, Innate</subject><subject>Immunoglobulins - blood</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunology</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interleukin-6 - blood</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</subject><subject>Longitudinal Studies</subject><subject>Lupus</subject><subject>Male</subject><subject>Mathematical models</subject><subject>Middle Aged</subject><subject>Piperazines - therapeutic use</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>T-Lymphocytes - metabolism</subject><subject>Teaching hospitals</subject><subject>Thiazoles - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1740-2522</issn><issn>2314-8861</issn><issn>1740-2530</issn><issn>2314-7156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFkktv1DAQgC0Eou3CiTMo4lIJtNSv2PEFCUU8VlpED-VsTWxn4yWJWzuh6r_HS8qKcuFky_P583hmEHpB8DtCyvKCYoIvCJOM4kfolEiO17Rk-PFxT-kJOktpj3Heq-opOqGEKIklO0Vt3cG4c6kIbbEZhnkMfdh5A31xGUPr-xzxY3EJk3fjlIpbP3VF3cUwelN8vXN98LbYuvmHGzwcyKlzRR3mmNzBeBUdTEO--Qw9aaFP7vn9ukLfP328qr-st98-b-oP27XJGU9rVQrXYCtLfPgUt1YSaAjBrFSNhMaaqqqUA6kMECyMAihZyRVmsuWYS2ArtFm8NsBeX0c_QLzTAbz-fRDiTkOcvOmdNoJUrRGUW5C8caBAMGukkE1LlRQ0u94vruu5GZw1-RsR-gfSh5HRd3oXfmqGMWcVyYLze0EMN7NLkx58Mq7vYXRhTrqilOX3cx9W6PU_5D7XcMyV0lUplFSS8gy9XSATQ0rRtcdUCNaHSdCHoullEjL96u_sj-yf1mfgzQJ0frRw6_9je7nALiOuhSPMeSW4YL8AvonEFw</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Hamšíková, Eva</creator><creator>Vonka, Vladimír</creator><creator>Humlová, Zuzana</creator><creator>Roth, Zdeněk</creator><creator>Šterzl, Ivan</creator><creator>Králíková, Petra</creator><creator>Klamová, Hana</creator><creator>Janatková, Ivana</creator><creator>Malíčková, Karin</creator><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20100101</creationdate><title>Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment</title><author>Hamšíková, Eva ; Vonka, Vladimír ; Humlová, Zuzana ; Roth, Zdeněk ; Šterzl, Ivan ; Králíková, Petra ; Klamová, Hana ; Janatková, Ivana ; Malíčková, Karin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c530t-956eb0d75020104dd71ab110359b7abdc8889ea79ca106c9aa53549037f4047a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>C-Reactive Protein - analysis</topic><topic>Complement System Proteins - analysis</topic><topic>Dasatinib</topic><topic>E coli</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxyurea - therapeutic use</topic><topic>Imatinib Mesylate</topic><topic>Immune system</topic><topic>Immunity, Innate</topic><topic>Immunoglobulins - blood</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunology</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interleukin-6 - blood</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</topic><topic>Longitudinal Studies</topic><topic>Lupus</topic><topic>Male</topic><topic>Mathematical models</topic><topic>Middle Aged</topic><topic>Piperazines - therapeutic use</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>T-Lymphocytes - metabolism</topic><topic>Teaching hospitals</topic><topic>Thiazoles - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamšíková, Eva</creatorcontrib><creatorcontrib>Vonka, Vladimír</creatorcontrib><creatorcontrib>Humlová, Zuzana</creatorcontrib><creatorcontrib>Roth, Zdeněk</creatorcontrib><creatorcontrib>Šterzl, Ivan</creatorcontrib><creatorcontrib>Králíková, Petra</creatorcontrib><creatorcontrib>Klamová, Hana</creatorcontrib><creatorcontrib>Janatková, Ivana</creatorcontrib><creatorcontrib>Malíčková, Karin</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Clinical &amp; developmental immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamšíková, Eva</au><au>Vonka, Vladimír</au><au>Humlová, Zuzana</au><au>Roth, Zdeněk</au><au>Šterzl, Ivan</au><au>Králíková, Petra</au><au>Klamová, Hana</au><au>Janatková, Ivana</au><au>Malíčková, Karin</au><au>Berzins, Stuart</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment</atitle><jtitle>Clinical &amp; developmental immunology</jtitle><addtitle>Clin Dev Immunol</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>2010</volume><issue>2010</issue><spage>1</spage><epage>17</epage><pages>1-17</pages><issn>1740-2522</issn><issn>2314-8861</issn><eissn>1740-2530</eissn><eissn>2314-7156</eissn><abstract>In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component of complement, the C-reactive protein, interleukin 6, the composition of lymphocyte population and the production of some cytokines by stimulated CD3+ cells. Eleven of these patients were followed longitudinally. After treatment with hydroxyurea, interferon alpha, imatinib mesylate and dasatinib, or various combinations thereof, hematological remission was achieved in all patients and complete cytogenetic remission in nine of them. There was a nearly general tendency towards normalization of the abnormalities observed in the patients at their enrollment.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Puplishing Corporation</pub><pmid>21197073</pmid><doi>10.1155/2010/137320</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1740-2522
ispartof Clinical & developmental immunology, 2010-01, Vol.2010 (2010), p.1-17
issn 1740-2522
2314-8861
1740-2530
2314-7156
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c618fc624da74bea9a63dc767bf29762
source Wiley Online Library Open Access; Publicly Available Content (ProQuest); PubMed Central
subjects Adult
Antineoplastic Agents - therapeutic use
Benzamides
C-Reactive Protein - analysis
Complement System Proteins - analysis
Dasatinib
E coli
Female
Humans
Hydroxyurea - therapeutic use
Imatinib Mesylate
Immune system
Immunity, Innate
Immunoglobulins - blood
Immunologic Factors - therapeutic use
Immunology
Interferon-alpha - therapeutic use
Interleukin-6 - blood
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy
Longitudinal Studies
Lupus
Male
Mathematical models
Middle Aged
Piperazines - therapeutic use
Protein Kinase Inhibitors - therapeutic use
Pyrimidines - therapeutic use
T-Lymphocytes - metabolism
Teaching hospitals
Thiazoles - therapeutic use
Treatment Outcome
title Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A26%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20of%20Immunological%20Profiles%20in%20Patients%20with%20Chronic%20Myeloid%20Leukemia%20in%20the%20Course%20of%20Treatment&rft.jtitle=Clinical%20&%20developmental%20immunology&rft.au=Ham%C5%A1%C3%ADkov%C3%A1,%20Eva&rft.date=2010-01-01&rft.volume=2010&rft.issue=2010&rft.spage=1&rft.epage=17&rft.pages=1-17&rft.issn=1740-2522&rft.eissn=1740-2530&rft_id=info:doi/10.1155/2010/137320&rft_dat=%3Cproquest_doaj_%3E2292562701%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c530t-956eb0d75020104dd71ab110359b7abdc8889ea79ca106c9aa53549037f4047a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=856979724&rft_id=info:pmid/21197073&rfr_iscdi=true